(NEW YORK) -- Pinya XP (OTC: PNXP) launches blockchain verification platform for biotech and gene therapy industry.
The partnership with True Cut will develop a comprehensive genetic database with Pinya XP's GROOVY 2.0 hyperledger centralized blockchain authentication platform, creating an end-to-end solution that verifies product authenticity while protecting genetic intellectual property.
Biotech Blockchain
This partnership not only positions PNXP as a supply chain logistics platform, but also as an emerging biotechnology play in pharmaceutical and gene therapy sectors, leveraging blockchain verification for genetic authentication and biometric tracking across therapeutic applications.
Some analysis projects the pharmaceutical blockchain market to reach $25.60 billion by 2030, driven by the growing issue of counterfeit medication in global supply-chains.
MEME Coin
The company is also planning launch of GroovySol, a Solana blockchain-based meme token that will integrate with its existing Groovy Rewards program, converting centralized loyalty points into decentralized cryptocurrency assets. Launch of MEME coin could quickly put PNXP on map with retail traders in the highly active Solana community.
Valuation Analysis
The company currently has only 75 million shares authorized, of which 25 million is issued and outstanding. If we use 40 million outstanding, to account for future dilution into our formula, a target valuation of $8-10 million still yields price target of $0.20-$0.25 per share.
PNXP current trades just over $0.01 per share.
Disclosures and Disclaimer:
THE MATERIAL HEREIN DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.
This reports contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
Ludlow Research (“Ludlow”), and its parent company Ludlow Consulting, LLC, are not registered broker-dealers or investment advisers with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”), or any state securities regulatory authority.
Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encouraged to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow was not compensated at the time of this research alert, but, through affiliates, may own position in underlying securities, and thus should be considered a conflict of interest when reviewing this material. Investments is speculative ‘penny stocks’, as defined by the SEC, may involve a high degree of risk.
INVESTORS ARE HIGHLY ENCOURAGED TO CONSULT WITH A FINANCIAL ADVISOR BEFORE MAKING ANY AND ALL INVESTMENT DECISIONS.